Novartis AG
Research Novartis AG (NVS) on Bullrun: valuation model: 11.0% undervalued, market cap USD 263.31B, P/E 21.7, dividend yield 3.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNVS
- ExchangeNYSE
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal11.0% undervalued
- Market capUSD 263.31B
- P/E21.7
- Dividend yield3.3%
- Financial periodQ2 2026
- RevenueUSD 14.95B
- Net incomeUSD 3.26B
- Free cash flowUSD 5.12B
- Gross margin75.2%
Valuation Snapshot
Bullrun's latest valuation model marks Novartis AG as 11.0% undervalued; latest market cap is USD 263.31B; P/E is 21.7; dividend yield is 3.3%.
Peer valuation comparison
Latest P/E is 21.7x versus a Healthcare sector median of 24.67x (12.0% below).
Latest dividend yield is 3.32% versus a Healthcare sector median of 1.84% (80.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 56.67B | USD 13.98B | USD 15.24B | 75.8% | 7.15 | USD 11.44B | USD 35.38B | USD 46.13B |
| FY2024 | USD 51.72B | USD 11.94B | USD 13.81B | 75.2% | 5.87 | USD 11.46B | USD 31.26B | USD 44.05B |
| FY2023 | USD 46.66B | USD 14.85B | USD 11.71B | 73.3% | 7.1 | USD 13.39B | USD 26.35B | USD 46.67B |
| FY2022 | USD 43.46B | USD 6.96B | USD 12.00B | 73.4% | 3.17 | USD 7.52B | USD 27.91B | USD 59.34B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 263.31B | 21.7 | 3.3% | 4.77 |
| 2025 | 2025-12-31 | USD 263.08B | 19.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 192.20B | 16.6 | 3.9% | 3.78 |
| 2023 | 2023-12-29 | USD 207.54B | 27.1 | 3.4% | 3.47 |
| 2022 | 2022-12-30 | USD 195.14B | 9.3 | 3.7% | 3.36 |
| 2021 | 2021-12-31 | USD 195.49B | 8.2 | 3.9% | 3.38 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 4.77 USD, yield 3.3%.
| Year | Dividends/share |
|---|---|
| FY2024 | 3.78 USD |
| FY2023 | 3.47 USD |
| FY2022 | 3.36 USD |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6);
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Novartis AG overvalued or undervalued?
Bullrun's valuation model currently marks Novartis AG as 11.0% undervalued.
What is Novartis AG's market cap?
Novartis AG's market capitalization is USD 263.31B.
What is Novartis AG's P/E ratio?
Novartis AG's price-to-earnings (P/E) ratio is 21.7.
Does Novartis AG pay a dividend?
Novartis AG has a dividend yield of 3.3%.
What does Novartis AG do?
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.